Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors

Annals of Oncology

Volumn 22, Issue 2, 2011, Pages 431-437

  Boss, D S ^a   Witteveen, P O ^b   van der Sar, J ^a   Lolkema, M P ^b   Voest, E E ^b   Stockman, P K ^c   Ataman, O ^c   Wilson, D ^c   Das, S ^c   Schellens, J H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Aurora kinase inhibitor; AZD1152; Pharmacokinetics; Phase I; Safety; Solid tumors

Indexed keywords

AURORA B KINASE; BARASERTIB;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; COLORECTAL CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPEPSIA; ECZEMA; ESOPHAGUS CANCER; FATIGUE; FEMALE; FLANK PAIN; HEAD AND NECK CANCER; HEMATURIA; HUMAN; HYPERHIDROSIS; LEUKOPENIA; LUNG CANCER; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPTIMAL DRUG DOSE; PANCREAS CANCER; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEINURIA; RHINOPHARYNGITIS; SIDE EFFECT; SKIN CANCER; SOFT TISSUE CANCER; SOLID TUMOR; STOMACH CANCER; STOMATITIS; VOMITING; XEROSTOMIA;

EID: 79251556865     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq344     Document Type: Article

References (25)

1. Andrews PD. Aurora kinases: shining lights on the therapeutic horizon? Oncogene 2005; 24: 5005-5015.
2. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003; 4: 842-854.
3. Ota T, Suto S, Katayama H et al. Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res 2002; 62: 5168-5177.
4. Kanda A, Kawai H, Suto S et al. Aurora-B/AIM-1 kinase activity is involved in Ras-mediated cell transformation. Oncogene 2005; 24: 7266-7272.
5. Wood KW, Cornwell WD, Jackson JR. Past and future of the mitotic spindle as an oncology target. Curr Opin Pharmacol 2001; 1: 370-377.
6. Gautschi O, Heighway J, Mack PC et al. Aurora kinases as anticancer drug targets. Clin Cancer Res 2008; 14: 1639-1648.
7. Boss DS, Beijnen JH, Schellens JH. Clinical experience with aurora kinase inhibitors: a review. Oncologist 2009; 14: 780-793.
8. Mortlock AA, Foote KM, Heron NM et al. Discovery, synthesis and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of Aurora B kinase. J Med Chem 2007; 50: 2213-2224.
9. Keen N, Brown E, Crafter C et al. Biological characterisation of AZD1152, a highly potent and selective inhibitor of aurora kinase activity. Clin Cancer Res 2005; 11: 183 (Abstr B220).
10. Wilkinson RW, Odedra R, Heaton SP et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 2007; 13: 3682-3688.
11. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
12. Simon R, Freidlin B, Rubinstein L et al. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997; 89: 1138-1147.
13. de Jonge M, Eskens FH, Gelderblom H et al. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J Clin Oncol 2009; 27: 5094-5101.
14. Cohen RB, Jones SF, Aggarwal C et al. A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res 2009; 15: 6694-6701.
15. Traynor AM, Hewitt M, Liu G et al. Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol 2010 Apr. 13 [epub ahead of print].
16. Infante J, Dees EC, Cohen RB et al. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MLN8237, a selective Aurora A kinase inhibitor, in the United States. Eur J Cancer Suppl 2008; 6(12): 90-91 (Abstr 280).
17. Plummer ER, Calvert H, Arkenau H et al. A dose-escalation and pharmacodynamic study of AT9283 in patients with refractory solid tumours. J Clin Oncol 2008; 26(15S): 116s (Abstr 2519).
18. Renshaw JS, Patnaik A, Gordon M et al. A phase I two arm trial of AS703569 (R763), an orally available aurora kinase inhibitor, in subjects with solid tumors: preliminary results. J Clin Oncol 2007; 25(18S): 622s (Abstr 14130).
19. Robert F, Hurwitz H, Verschraegen CF et al. Phase 1 trial of SNS-314, a novel selective inhibitor of aurora kinases A, B, and C, in advanced solid tumor patients. J Clin Oncol 2008; 26(15S): 638s (Abstr 14642).
20. Jones SF, Burris HA III, Dumez H et al. Phase I accelerated dose-escalation, pharmacokinetic (PK) and pharmacodynamic study of PF-03814735, an oral aurora kinase inhibitor, in patients with advanced solid tumors: preliminary results. J Clin Oncol 2008; 26(15S): 116s (Abstr 2517).
21. Foran JM, Ravandi F, O'Brien SM et al. Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia. J Clin Oncol 2008; 26(15S): 116s (Abstr 2518).
22. Carpinelli P, Moll J. Aurora kinase inhibitors: identification and preclinical validation of their biomarkers. Expert Opin Ther Targets 2008; 12: 69-80.
23. Nair JS, Tse A, Keen N, Schwartz GK. A novel Aurora B kinase inhibitor with potent anticancer activity either as a single agent or in combination with chemotherapy. J Clin Oncol 2004; 22(14S): (Abstr 9568).
24. Yang J, Ikezoe T, Nishioka C et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 2007; 110: 2034-2040.
25. Tao Y, Zhang P, Girdler F et al. Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152. Oncogene 2007; 27: 3244-3255.